B of A Securities Maintains Buy on Sarepta Therapeutics, Raises Price Target to $213
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained its Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raised the price target from $166 to $213.
June 21, 2024 | 10:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities has maintained its Buy rating on Sarepta Therapeutics and raised the price target from $166 to $213, indicating strong confidence in the company's future performance.
The raised price target from $166 to $213 by B of A Securities suggests a strong positive outlook for Sarepta Therapeutics. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100